Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Histone deacetylase 6 (HDAC6) controls JAK2 translation and protein stability, and has been implicated in JAK2-driven diseases best exemplified by Myeloproliferative Neoplasms (MPNs).
|
31750881 |
2020 |
Myeloproliferative disease
|
0.500 |
AlteredExpression
|
group |
BEFREE |
AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis.
|
31837568 |
2020 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Developing Janus kinase 2 (JAK2) inhibitors has become a significant focus for small-molecule drug discovery programs in recent years because the inhibition of JAK2 may be an effective approach for the treatment of myeloproliferative neoplasm.
|
31746601 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Identification of janus kinase 2 (JAK2) mutation even in absence of myeloproliferative disorders (MPNs) was found to be related to venous thromboembolism occurrence.
|
31229378 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Primary and post-ET/PV myelofibrosis are myeloproliferative neoplasms harboring in most cases driving mutations in JAK2, CALR or MPL, and a variable number of additional mutations in other genes.
|
31446640 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The most prominent genes of this locus are programmed death ligands 1 and 2 (PDL1/PDL2), with the amplification of PDL1 being a hallmark of both classical Hodgkin and primary mediastinal B cell lymphoma, and Janus kinase 2 (JAK2), which is point-mutated in myeloproliferative neoplasms and other myeloid malignancies, and rearranged in PCM1-JAK2-positive myeloid/lymphoid neoplasms with eosinophila.
|
30132131 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype.
|
30516848 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms are present in 35%-50% of European patients and are usually associated with the JAK2-V617F mutation.
|
30828850 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Ruxolitinib is a small molecule JAK-2 inhibitor approved for the treatment of certain myeloproliferative neoplasms.
|
29651917 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
TERT and JAK2 polymorphisms define genetic predisposition to myeloproliferative neoplasms in Japanese patients.
|
31571131 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
JAK2 variants were detected at a higher frequency in the MPN>AML cohort (15.3%) in comparison with the MPN (4.6%; P < .001) and AML cohorts (5.2%; P < .001).
|
30811597 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases.
|
30829649 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
Janus kinase 2 (JAK2) inhibitors represent a promising therapeutic class of anticancer agents against many myeloproliferative disorders.
|
31805692 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
JAK2 plays a critical role in JAK/STAT signaling pathway and in patho-mechanism of myeloproliferative disorders and autoimmune diseases.
|
30617940 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The V617F mutation in the JH2 domain of JAK2 is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV).
|
31697804 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms.
|
29589523 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
|
31704857 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Activating mutations in JAK2 have been described in patients with various hematologic malignancies including acute myeloid leukemia (AML) and myeloproliferative neoplasms.
|
31299252 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The discovery of a mutation in the Janus Kinase 2 gene in 2005 spurred significant progress in the field of myeloproliferative neoplasms.
|
30987952 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Sequential genotyping for phenotype-driver mutations in JAK2 (exon 14), CALR (exon 9), and MPL (exon 10) is recommended in patients with myeloproliferative neoplasms.
|
31135094 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The hallmark of <i>BCR-ABL1</i>-negative myeloproliferative neoplasms (MPNs) is the presence of a driver mutation in <i>JAK2, CALR</i>, or <i>MPL</i> gene.
|
31106152 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and CALR genes; however, 10%-15% of cases are triple negative (TN).
|
30295334 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) share similar molecular characteristics in that they frequently harbor hotspot mutations in JAK2, CALR or MPL, leading to activated JAK/STAT signaling.
|
31071164 |
2019 |
Myeloproliferative disease
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The Janus kinase 2 (<i>JAK2</i>) V617F mutation is common in patients with breakpoint cluster region-Abelson1 (<i>BCR-ABL1</i>)-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis, but is rarely detected in <i>BCR-ABL1-</i>positive chronic myeloid leukemia (CML) patients.
|
31123683 |
2019 |
Myeloproliferative disease
|
0.500 |
Biomarker
|
group |
BEFREE |
The JAK2-STAT signaling pathway plays a critical role in myeloproliferative neoplasms (MPN).
|
30717771 |
2019 |